

RespireRx Pharmaceuticals Inc.
Form 4
January 20, 2017

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Margolis Jeff Eliot

(Last) (First) (Middle)

C/O RESPIRERX
PHARMACEUTICALS INC., 17
PARK AVENUE, #201

(Street)

GLEN ROCK, NJ 07452

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
RespireRx Pharmaceuticals Inc.
[RSPI]

3. Date of Earliest Transaction
(Month/Day/Year)
01/18/2017

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

☐ Director ☐ 10% Owner
☒ Officer (give title below) ☐ Other (specify
below)
VP, Treasurer & Secretary

6. Individual or Joint/Group Filing(Check
Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount		Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form
displays a currently valid OMB control
number.**

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: RespireRx Pharmaceuticals Inc. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Options (to purchase shares of Common Stock)	\$ 3.9	01/18/2017		A ⁽¹⁾		35,000 ⁽¹⁾		⁽²⁾	01/18/2022	Common Stock	35,000
Common Stock Options (to purchase shares of Common Stock)	\$ 3.9	01/18/2017		A ⁽¹⁾		15,000 ⁽¹⁾		⁽²⁾	01/18/2022	Common Stock	15,000
Common Stock Warrants (right to buy)	\$ 6.9225 ⁽⁷⁾							⁽⁸⁾	09/30/2020	Common Stock	2,423 ⁽⁷⁾
Common Stock Warrants (right to buy)	\$ 6.9225 ⁽⁷⁾							⁽⁸⁾	09/30/2020	Common Stock	2,423 ⁽⁷⁾
Common Stock Options (to purchase shares of Common Stock)	\$ 7.3775 ⁽⁷⁾							⁽⁹⁾	03/31/2021	Common Stock	40,000 ⁽⁷⁾
Common Stock Options	\$ 7.3775 ⁽⁷⁾							⁽⁹⁾	03/31/2021	Common Stock	6,154 ⁽⁷⁾

(to
purchase
shares of
Common
Stock)

Common
Stock
Options

(to \$ 7.3775
purchase (7)

(9)

03/31/2021

Common
Stock

21,539
(7)

shares of
Common
Stock)

Common
Stock
Options

(to \$ 7.3775
purchase (7)

(9)

03/31/2021

Common
Stock

6,154
(7)

shares of
Common
Stock)

Common
Stock
Options

(to \$ 6.396
purchase (7)

(10)

08/18/2022

Common
Stock

13,847
(7)

shares of
Common
Stock)

Common
Stock
Options

(to \$ 6.396
purchase (7)

(10)

08/18/2022

Common
Stock

7,693
(7)

shares of
Common
Stock)

Common
Stock
Options

(to \$ 6.396
purchase (7)

(10)

08/18/2022

Common
Stock

7,693
(7)

shares of
Common
Stock)

Common \$ 6.396
Stock (7)

(10)

08/18/2022

Common
Stock

1,539
(7)

Options
(to
purchase
shares of
Common
Stock)

Common
Stock
Options
(to
purchase
shares of
Common
Stock)

\$ 8.125
(7)

(11)

06/30/2022

Common
Stock

24,616
(7)

Common
Stock
Options
(to
purchase
shares of
Common
Stock)

\$ 8.125
(7)

(11)

06/30/2022

Common
Stock

6,154
(7)

Common
Stock
Options
(to
purchase
shares of
Common
Stock)

\$ 8.125
(7)

(11)

06/30/2022

Common
Stock

13,847
(7)

Common
Stock
Options
(to
purchase
shares of
Common
Stock)

\$ 8.125
(7)

(11)

06/30/2022

Common
Stock

1,539
(7)

Common
Stock
Options
(to
purchase
shares of
Common
Stock)

\$ 16.25
(7)

(12)

07/17/2019

Common
Stock

6,994
(7)

Common \$ 16.25

(12)

07/17/2019

Common

3,077

Stock Options (to purchase shares of Common Stock)	(7)					Stock	(7)
Common Stock Options (to purchase shares of Common Stock)	\$ 16.25	(12)	07/17/2019	Common Stock	1,119		(7)
Common Stock Options (to purchase shares of Common Stock)	\$ 16.25	(12)	07/17/2019	Common Stock	4,196		(7)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Margolis Jeff Eliot C/O RESPIRERX PHARMACEUTICALS INC. 17 PARK AVENUE, #201 GLEN ROCK, NJ 07452	X		VP, Treasurer & Secretary	

Signatures

/s/ Jeff E. Margolis
01/20/2017

Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These awards were made to the reporting person or his designee and were issued to Trusts at his direction for estate planning purposes.
- (2) These Common Stock Options vest in three installments: 25 percent on January 18, 2017 (the grant date), 25 percent on March 31, 2017, and 50 percent on June 30, 2017.
- (3) These securities are held in a trust for the benefit of Mr. Margolis's spouse. Mr. Margolis's spouse is a trustee of the trust.

Edgar Filing: RespireRx Pharmaceuticals Inc. - Form 4

- These securities are held in trusts for the benefit of Mr. Margolis's children. Mr. Margolis's spouse is a trustee of these trusts. Mr.
- (4) Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
- These securities are held in trusts for the benefit of Mr. Margolis's children. Mr. Margolis is a trustee of these trusts. Mr. Margolis
- (5) disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
- (6) These securities are held in a trust for the benefit of Mr. Margolis. Mr. Margolis's Spouse is a trustee of the trust.
- (7) The exercise price and number of shares of these securities have been adjusted to reflect the Company's 325-to-1 reverse stock split effective September 1, 2016.
- These Warrants were acquired by Mr. Margolis and his spouse in his capacity as President of Aurora Capital LLC, which served as
- (8) placement agent in the Company's unit offering with each unit consisting of one share of common stock and warrants to purchase two additional shares of common stock, and represent his share of the Placement Agent Warrants awarded at each closing of that transaction. The warrants are currently exercisable.
- (9) These Common Stock Options vest in four equal installments: 25 percent on March 31, 2016 (the grant date), 25 percent on June 30, 2016, 25 percent on September 30, 2016, and 25 percent on December 31, 2016.
- (10) These Common Stock Options vest in four equal installments: 25 percent on December 31, 2015, 25 percent on March 31, 2016, 25 percent on June 30, 2016, and 25 percent on September 30, 2016.
- (11) These Common Stock Options vested in three installments: 50 percent on June 30, 2015, 25 percent on September 30, 2015, and 25 percent on December 31, 2015, and are all currently vested and exercisable.
- (12) These Common Stock Options vested in three equal installments on July 17, 2014, September 30, 2014 and December 31, 2014, and are all currently vested and exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.